alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 901–925 of 1,094 studies in Digital health tools (page 37 of 44) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

What “Digital health tools” covers

Digital health tools — Apps, wearables, online tests and other technology used to detect, monitor or support people with dementia.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

The role for artificial intelligence in identifying combination therapies for Alzheimer’s disease

✓ Peer-reviewed alzhub usefulness score 39 out of 100. The Journal of Prevention of Alzheimer s Disease 2025-10-27

Despite substantial investment in biomedical and pharmaceutical research over the past two decades, the global prevalence of Alzheimer's disease (AD) and AD-related dementias (AD/ADRD) is still rising. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cornea Oculomics: A Clinical Blueprint for Extending Corneal Diagnostics and Artificial Intelligence in Systemic Health Insights

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Diagnostics 2025-03-06

Oculomics is an emerging field that leverages ophthalmic imaging data to identify biomarkers of systemic disease, facilitating early diagnosis and risk stratification. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Human-Centered Ambient and Wearable Sensing for Automated Monitoring in Dementia Care: A Scoping Review

✓ Peer-reviewed alzhub usefulness score 39 out of 100. IEEE Internet of Things Journal 2026-01-22

We conducted a scoping review to map the rapidly evolving landscape of wearable and ambient sensing technologies for monitoring people with dementia across home and institutional settings. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Older Adults' Reasons for Using Technology while Aging in Place

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Gerontology 2015-06-04

The level of technology use in the context of aging in place is influenced by six major themes: challenges in the domain of independent living; behavioral options; personal thoughts on technology use; influence of the social network; influence of organizations, and the role of the physical environment. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Evolution of Parkinson's disease during 4 years of bilateral deep brain stimulation of the subthalamic nucleus

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Movement disorders : official journal of the Movement Disorder Society 2006-05-01

Patients with advanced Parkinson's disease (PD) and motor complications can obtain significant symptom improvement by deep brain stimulation (DBS) of the subthalamic nucleus (STN). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

ALS and other motor neuron diseases

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Continuum (Minneapolis, Minn.) 2014-10-01

TAR DNA binding protein 43 kDa (TDP-43), for instance, has been shown to cause frontotemporal dementia as well as some cases of familial ALS, and is associated with frontotemporal dysfunction in ALS. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Comparison of Feature Selection Techniques in Machine Learning for Anatomical Brain MRI in Dementia

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Neuroinformatics 2016-07-01

We present a comparative split-half resampling analysis of various data driven feature selection and classification methods for the whole brain voxel-based classification analysis of anatomical magnetic resonance images. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Barriers to limiting the practice of feeding tube placement in advanced dementia

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of palliative medicine 2003-12-01

We find a notable discord between physician opinion, reported practice, and the literature regarding PEG tubes in advanced dementia that reveals some of the barriers to decreasing the referral of these patients for PEG. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Acoustic analysis in the differentiation of Parkinson's disease and major depression

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of psycholinguistic research 1992-09-01

In its early stages, Parkinson's disease (P.D.) may be difficult to distinguish from major depression (M.D.) leading to inappropriate management. 2 key findings →

Participants: 30 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Integrative and interpretable framework to unveil the neurophysiological fingerprint of Alzheimer’s disease and mild cognitive impairment: A machine learning-SHAP approach

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of Applied Biomedicine 2025-06-13

Dementia and mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) are neurological pathologies associated with disruptions in brain electromagnetic activity, typically studied using magnetoencephalography (MEG) and electroencephalography (EEG). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

An Artificial Intelligence-Driven Multimorbidity Framework Reveals a Shared Metabolic and Immune Core Across Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Biomedicines 2026-02-16

Across AD, ALS, and FTD, a convergent multimorbidity architecture centered on a shared metabolic and immune core was identified, accompanied by prominent neurobehavioral processes and intermediate systems including gastrointestinal, endocrine, hematological, hepatic, and sensory pathways. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Mapping knowledge landscapes and emerging trends in digital biomarkers for dementia in older adults: A scoping and bibliometric analysis

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Archives of Gerontology and Geriatrics Plus 2025-04-09

This paper presents a systematic bibliometric analysis of the research landscape at the intersection of Alzheimer's disease and gerontechnology, identifying key contributors, research hotspots, and emerging trends. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Identifying syntactic biomarkers of cognitive impairment in Mandarin-speaking older adults by applying machine learning approaches across multiple speech tasks

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Aphasiology 2025-05-28

The use of linguistic biomarkers for detecting cognitive decline and early stages of dementia has demonstrated great potential due to its low-cost and non-invasive nature, especially towards a large aging population. 3 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed